JWK006
/ Genevector Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 12, 2024
Safety and Efficacy of a Single Subretinal Injection of JWK006 Gene Therapy in Subjects With Stargardt Disease(STGD1)
(clinicaltrials.gov)
- P1/2 | N=9 | Active, not recruiting | Sponsor: West China Hospital
Gene therapy • New P1/2 trial • Gene Therapies • Inherited Retinal Dystrophy • Ophthalmology • Retinal Disorders
1 to 1
Of
1
Go to page
1